medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2011, Number 09

<< Back Next >>

Ginecol Obstet Mex 2011; 79 (09)

Hormonal contraception as a risk factor for developing cervical cancer: biological, epidemiological and immunological evidence

Castro RJI, Hernández GC, Madrid MV

Language: Spanish
References: 46
Page: 537-543
PDF size: 183.75 Kb.


ABSTRACT

Background: Cervical cancer has been extensively studied, as well as the various risk factors for that cancer. One such factor is the prolonged use of hormonal contraceptives.
Objective: To report the biological, immunological and epidemiological findings arising from the use of oral contraceptives and their relation to cervical cancer.
Material and methods: Retrospective study based on information published in national and international literature.
Conclusions: Controversy persists between the epidemiological data and experimental biological association between hormonal contraceptives and cancer induced by HPV. It is important to consider the biological findings because in Mexico the use of hormonal contraceptives is very broad and the number of cases of cervical cancer and only extensive epidemiological studies will clarify this controversy.


REFERENCES

  1. Galloway D. Is vaccination against human papillomavirus a possibility? Lancet 1998;351(suppl III):22-24.

  2. Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.

  3. Muñoz N, Bosch X. Cervical cancer and human papillomavirus: epidemiological evidence and perspectives for prevention. Salud Pública Mex 1997;39:274-282.

  4. Ho G, Bierman R, Beardsley L, Chang C, Burk D. Natural history of cervical papillomavirus infection in young women. N Eng J Med 1998;338:423-428.

  5. Tchabo J, Brinton L, Copeland C. Epp J. Determinants of genital human papilloma-viruses infection in low-income women in Washington D.C. Sex Trans Dis 1993;20:279-285.

  6. Lazcano-Ponce E, Herrero R, Munoz N, Cruz A, Shah K, et al. Epidemiology of HPV infection among mexican women with normal cervical citology. Int J Cancer 2001;91:412-420.

  7. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci 2005;102:2490-2495.

  8. Bradlow HL, Sepkovic DW. Steroid as procarcinogenic agents. Ann NY Acad Sci 2004;1028:216-232.

  9. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes F, et al. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 2000;60:1267-1275.

  10. Arbeit JM, Hoeley PM, Hanaham D. Chronic estrogen induced cervical and vaginal squamous carcinogenesis in HPV16 transgenic mice. Proc Natl Acad Sci USA 1996;93:2930-2935.

  11. Riley RR, Duensing S, Breake T, Munguer K, Lambert PF, et al. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Research 2003;63:4862-4871.

  12. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci 2005;102:2490-2495.

  13. Delvene P, Herman L, Kholod N, Coberg JH, Herf M, et al. Role of hormone cofactors in the human papillomavirus-induced carcino-genesis of the uterine cervix. Mol Cell Endocrinol 2007;264:1-5.

  14. Strahle U, Klock G, Schutz G. A DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression. Proc Natl Acad Sci 1987;84:7871-7875.

  15. Chan W, Klock G, Bernard H. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 1989;63:3261-3269.

  16. Antinone MJ, Birrer MJ, Patel D, Nader L, McCance DJ. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J 1996;15:1950-1960.

  17. Chon T, Chan W Bernard H. Transcrptional activation of human papillomavirus 16 by nuclear factor 1, AP1, steroid receptors and a possibly novel transcription factor, PVF: a model for the composition of genital papillomavirus enhancers. Nucleic Acids Research 1990;18:465-470.

  18. Men-Hsun Wu, Yi-Hsin Chan J, Pei-Yao Liu, Shu-Ting Liu, Shih-Ming Huang. Human papillomavirus E2 protein associates with nuclear receptors to stimulate nuclear receptor-and E2-dependent transcriptional activations in human cervical carcinoma cells. Int J Biochem & Cell Biol 2007;39:413-425.

  19. Díaz-González, Sacnité del Mar, Castro JI y Madrid-Marina V. Tesis de Maestría en Ciencias de la Salud Pública: Efecto del 17b-estradiol y progesterona en la proliferación de células cervicales y en la regulación de los oncogenes E6 y E7 del HPV-16. Instituto Nacional de Salud Pública. Junio 30, 2008.

  20. Men- Hsun Wu, James Yi-Hsin Chan, Pei-Yao Liu, Shu Ting Liu, Shih-Ming Huang. Human papillomavirus E2 protein associates with nuclear receptors to stimulate nuclear receptor- and E2-dependent transcriptional activations in human cervical carcinoma cells. Int. J Biochem 8i Cell Biol, 2007; 39:413-425.

  21. Chen YH, Huang LH, Chen TM. Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophysics Res Commun 1996;224:651-659.

  22. Mittal R, Tsutsumi K, Pater A, Pater MM. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol 1993;81:5-12.

  23. Webster K, Taylor A, Gaston K. Oestrogen and progesterone increase the levels of apoptosis induced by the human papillomavirus type 16 E2 and E7 proteins. J General Virol 2000;82:201-213.

  24. Moodley M, Moodley J, Chetty R, Herrington CS. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 2003;13:103-110.

  25. Moodley M, Sewart S, Herrington CS, Chetty R, Pegoraro R. The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression and cervical cancer. Int J Gynecol Cancer 2003;13:834-842.

  26. Shai A, Pitot HC, Lambert PF. P53 loss synergizes whit estrogen and papilomavirus oncogenes to induce cervical and breast cancers. Cancer Research 2008;68:2622-2631.

  27. Kumar A, Zhao Y, Meng G, Zeng M, et al. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator ADA3. Mol Cell Biol 2002;22:5801-5812.

  28. Meng G, Zhao Y, Nag A, Zeng M, et al. Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation. J Biol Chem 2004;279:54230-54240.

  29. Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008;110:S4-S7.

  30. Sanjosé S, Diaz M, Catellsagué X, Clifford G, Bruni L, et al. Worldwide prevalence and genotype distribution of cervical HPV in women with normal cytology. Lancet Infect Dis 2007;7:453-459.

  31. Restrepo HE, González J, Roberts E, Litvak J. Epidemiología y control del cáncer del cuello uterino en América Latina y el Caribe. Bol Of Sanit Panam 1987;102:578-592.

  32. SSA. Dirección General de Información y Evaluación del Desempeño. Secretaría de Salud. México 2001: Cancer Cervicouterino. SSA, 2002.

  33. Dirección General de Epidemiología. Secretaría de Salud. Registro histopatológico de neoplasias en México, 1994.

  34. Secretaría de Salud. Programa Nacional de Prevención y Control del Cáncer Cervicouterino 1995-2000. México, 1995.

  35. Bertram C. Evidence for practice: oral contraception and risk of cervical cancer. J Am Acad Nurse Pract 2004;16:455-461.

  36. McFarlnae N, Bazuaye PE, Jackson MD, Smikle M, Fletcher HM. Cervical Dysplasia and cancer and the use of hormonal contraceptives in Jamaica. BMC Women Health 2008;30:8-9.

  37. Deligeoroglou E, Michailidis E, CreatsasG. Oral contraceptive and reproductive system cancer. Ann NY Acad Sci 2003;997:199-208.

  38. MacFarlane-Anderson N, Bazuaye P, Jackson M, Smikle M, Fletcher H. Cervical dysplasia and cancer and the use of hormonal contraceptives in Jamaican women. BMC Women’s Health 2008;8:1-6.

  39. Vessey M, Painter R. Oral contraceptive use and cancer: findings in a large cohort study, l968-2004. Br J Cancer 2006;95:385-389.

  40. Appleby P, Beral V, Berrington A, Colin D, Francheschi S, et al. Cervical cancer an hormonal contraceptive. Lancet 2007;370:1591-1592.

  41. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomarirus infection: the IARC multicentric casecontrol study. Lancet 2002;359:1085-1092.

  42. Shapiro S, Rosenberg L, Hoffman M, Nelly JP, Cooper D, et al. Risk of invasive cancer of the cervix in relation to use of injectable progesterone contraceptives and combined estrogen/progesterone oral contraceptive. Cancer Causes Control 2003;14:485-495.

  43. Green J, Berrington A, Smith JS, Franceschi S, Appleby P, et al. Human papilloma-virus infection and use of oral contraceptive. Br J Cancer 2003;88:1713-1720.

  44. Juneja A, Sehgal A, Mitra AB, Pandey A. A survey on risk factors associated with cervical cancer. Indian J Cancer 2003;40:15-22.

  45. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J 2003;9:348-359.

  46. Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, et al. A case control study of risk factors for invasive cervical cancer among US women exposed to oncogenic types of HPV. Cancer Epidemiol Bio Prev 2004;13:1574-1582.




2020     |     www.medigraphic.com